Atrial Fibrillation Ablation Registry

NCT ID: NCT03075930

Last Updated: 2020-02-20

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 1250 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-01-12
• Study Completion Date: 2023-01-31

Brief Summary

This is a single centre prospective data registry. In this study atrial conduction characteristics of extended surface Electrocardiograms (esECG), biomarkers and genetic analysis will be performed before ablation, before discharge and 3 months after catheter ablation of atrial fibrillation (AF) and compared to routine clinical follow-up data.

The objective of this registry is to establish a data registry of patients undergoing ablation of AF. Supplementary to the routine clinical diagnostic an esECG and an analysis of biomarkers will be performed and compared to clinical and outcome data.

Detailed Description

Electro anatomical remodelling of the atria due to ageing or structural heart disease leads to AF which in turn leads to cardiac electrical and structural remodelling. In case of advanced remodelling restoration of sinus rhythm (SR) becomes more difficult and the results of catheter ablation are disappointing. Furthermore, there is no valid parameter to predict or diagnose recurrence of AF during SR after successful ablation, so repeated long-term electrocardiogram (ECG) recordings have to be performed to detect asymptomatic AF episodes in particular.

Thus, the rationale to establish a systematic review of patient data in a registry are:

• Self-termination AF leads to slight, persistent AF leads to more advanced cardiac remodelling, shown in altered atrial conduction properties
• Early recognition and therapy of AF improves the outcome, thus clinical parameter to predict or diagnose recurrence of AF during SR are desirable Ablation of AF is predominantely performed using standard endocardial transvenous technique of pulmonary veins isolation (PVI) by radiofrequency or cryoballoon ablation. For medical reasons specific ablation techniques like additional ablation lines or an epicardial approach is in discretion of the treating cardiologist. The esECG is measured by signal averaged routine 12-lead ECG with 3-5 supplementary leads before ablation, before discharge and 3 months after ablation. 2 tubes of EDTA plasma will be taken supplementary during routine venous puncture on admission and analysed for biomarkers and common gene variants.

During 5 years every participant receives an esECG before ablation, before discharge and three months after ablation. Routine follow-up data of each participant is included until 12 months of follow-up.

Patients who are included would also undergo a procedure without participation in this study. Risks (complications of procedures) are associated with the procedure and not with participation in the registry. The supplementary diagnostics performed for the registry are comprehensible to clinical routine ECG diagnostics. Extra (study-related) investigations consist of esECG (a signal averaged surface ECG with 3-5 supplementary leads at baseline before ablation), before discharge, and 3 months after ablation, and possibly also a body surface potential map (BSPM). These are always planned together with routine follow-up, no extra visits are necessary. The esECG and BSPM can be compared to regular ECGs, the only additional discomfort might be the number of leads. Furthermore 2 tubes of EDTA plasma blood will be taken supplementary at the routine admission venous puncture for further biomarker and common gene variants analysis.

Quality assurance plan: All data will be stored in 2 independent database. In the first database personal and contact informations are stored with a decent patient ID number in ascending order. In the other database all medical informations will be stored without personal data of the patient. The database has algorithm to prevent mesenteries and rudimentary checks for data integrity and consistency. List are provided for repeated parameters and all variables are explained if relevant. Standard operating procedures are provided for relevant steps in patient inclusion, measurements and data entry.

Because of the registry character no sample size calculation is provided yet. But after the first year of inclusion a data analysis will provide informations about an expected sample size. To date we calculate for an period of patient inclusion of 5 years.

Data inconsistency could not be avoided due to the registry character of this study and will marked in a respective way.

Statistical analysis will be performed after the first year of patients including logistic regression analysis to determine the discriminative power of the recorded ECG for the clinical outcome and recurrence of AF.

Conditions

Atrial Fibrillation (Paroxysmal); Atrial Fibrillation Recurrent; Atrial Fibrillation Common Gene Variants

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Extended Electrocardiogram

Elective patients receiving an AF ablation receiving a extended ECG

Extended Electrocardiogram

Intervention Type: DEVICE

ECG with 3 additional leads and a 5 minute recording

Body surface potential map

Elective patients receiving an AF ablation receiving a body surface potential map

Body surface potential map

Intervention Type: DEVICE

ECG with 184 leads and a 5 minute recording

Interventions

Extended Electrocardiogram

ECG with 3 additional leads and a 5 minute recording

Intervention Type: DEVICE

Body surface potential map

ECG with 184 leads and a 5 minute recording

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Documented self-terminating or persistent AF
• Scheduled for ablation of AF
• At least 18 years of age, mentally able and willing to give informed consent

Exclusion Criteria

• Emergency ablation
• Serious patient condition before ablation
• Physically or mentally unable to provide written informed consent
• Permanent atrial fibrillation

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RWTH Aachen University

OTHER

Sponsor Role: collaborator

Maastricht University Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Matthias D Zink

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Laurent Pison, Physician

Role: STUDY_DIRECTOR

Maastricht University

Ulrich Schotten, Physician

Role: PRINCIPAL_INVESTIGATOR

Maastricht University

Matthias D Zink, Physician

Role: STUDY_DIRECTOR

Maastricht University

Locations

Maastricht University

Maastricht, Limburg, Netherlands

Site Status: RECRUITING

Countries

Netherlands

Central Contacts

Matthias D Zink, Physician

Role: CONTACT

m.zink@maastrichtuniversity.nl

00491797523510

Ulrich Schotten, Physician

Role: CONTACT

schotten@maastrichtuniversity.nl

Facility Contacts

Matthias D Zink, Physician

Role: primary

m.zink@maastrichtuniversity.nl

00491797523510

Ulrich Schotten, Physician

Role: backup

schotten@maastrichtuniversity.nl

Other Identifiers

METC 16-4-208

Identifier Type: -

Identifier Source: org_study_id